Page 8 - John Redd News Today

Print By the time he tested positive for a coronavirus infection, Gary Herritz was feeling pretty sick. His scratchy throat had progressed to a dry cough, headache, joint pain and fever. A liver transplant recipient, he knew his compromised immune system made him vulnerable to a severe case of COVID-19. Herritz had read on Twitter about monoclonal antibody therapy, the type of treatment famously touted by Donald Trump after his release from Walter Reed National Military Medical Center. The Foo...

. (Tribune News Service) — By the time he tested positive for a coronavirus infection, Gary Herritz was feeling pretty sick. His scratchy throat had progressed to a dry cough, headache, joint pain and fever. A liver transplant recipient, he knew his compromised immune system made him vulnerable to a severe case of COVID-19. Herritz had read on Twitter about monoclonal antibody therapy, the type of treatment famously touted by Donald Trump after his release from Walter Reed National Mil...

Trump issues commendations to Operation Warp Speed members, including Fauci, Birx By Catherine Park Gen. Lloyd Austin says COVID-19 is the greatest threat America faces today Addressing the Senate Armed Services Committee, Austin, who served 41 years in the Army, vowed to surround himself with qualified civilians and include them in policy decisions. WASHINGTON - On his last day in office, President Donald Trump issued commendations to a number people for their contributions to Operation Warp S...

By the time he tested positive for covid-19 on Jan. 12, Gary Herritz was feeling pretty sick. He suspects he was infected a week earlier, during a medical appointment in which he saw health workers who were wearing masks beneath their noses or who had removed them entirely.

First published on With two highly effective coronavirus vaccines now being distributed across the country, the U.S. government’s announcement Thursday to set aside $2.6 billion for purchasing an antibody drug for COVID-19 may have raised a few eyebrows.  After all, the two currently authorized antibody drugs, from Regeneron and Eli Lilly, have not been widely used since the Food and Drug Administration cleared both in November. And the logistical issues that have hindered their launch haven...

Why a drug therapy that could ease record Covid hospitalizations has gone largely unused Erika Edwards © Provided by NBC News A drug that could protect high-risk Covid-19 patients from developing severe illness is sitting on shelves unused as a record number of people are hospitalized in the U.S. On Thursday, public health officials at the federal and state levels pleaded with the country to take advantage of its vast supply of monoclonal antibody treatments, the only availabl...

Demand is low for COVID-19 antibody drugs but shortages loom FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via...

Demand is low for COVID-19 antibody drugs but shortages loom Marilynn Marchione Updated:  Tags:  FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in...

10:15 EDT, 18 December 2020 U.S. health officials are seeing an astonishing lack of demand for COVID-19 medicines that may help keep infected people out of the hospital, drugs they rushed out to states over the past few weeks as deaths set new records. Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from these drugs, which supply antibodies to help the immune system fight the coronavirus. Only 5% to 20% of doses the federal government allo...

Marilynn Marchione FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via AP) December ...